These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 24399770)

  • 1. Tendering and value-based pricing: lessons from Italy on human papilloma virus vaccines.
    Garattini L; Van de Vooren K; Freemantle N
    J R Soc Med; 2014 Jan; 107(1):4-5. PubMed ID: 24399770
    [No Abstract]   [Full Text] [Related]  

  • 2. Pricing human papillomavirus vaccines: lessons from Italy.
    Garattini L; van de Vooren K; Curto A
    Pharmacoeconomics; 2012 Mar; 30(3):213-7. PubMed ID: 22233523
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-risk analysis of available cervix cancer vaccine: Situation analysis from Thailand.
    Wiwanitkit S; Wiwanitkit V
    J Cancer Res Ther; 2019; 15(6):1421. PubMed ID: 31898687
    [No Abstract]   [Full Text] [Related]  

  • 4. HPV vaccine strategies: the cost of HPV and the choice of vaccine.
    Morris SR
    Sex Transm Infect; 2009 Sep; 85(5):315-6. PubMed ID: 19773455
    [No Abstract]   [Full Text] [Related]  

  • 5. Do you approve of spending $300 million on HPV vaccination?: no.
    Lippman A; Boscoe M; Scurfield C
    Can Fam Physician; 2008 Feb; 54(2):175, 177, 179, 181. PubMed ID: 18272623
    [No Abstract]   [Full Text] [Related]  

  • 6. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL; Joura EA
    BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of different human papillomavirus vaccines in Singapore.
    Lee VJ; Tay SK; Teoh YL; Tok MY
    BMC Public Health; 2011 Mar; 11():203. PubMed ID: 21453537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. For debate: that Australia should continue using the quadrivalent vaccine.
    Wain G
    Sex Health; 2010 Sep; 7(3):235-7. PubMed ID: 21058496
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis.
    Jiang Y; Ni W; Wu J
    BMJ Open; 2019 Nov; 9(11):e031186. PubMed ID: 31767588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
    Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
    Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (Not) warts and all.
    Hammond P
    BMJ; 2008 Oct; 337():a2186. PubMed ID: 18948345
    [No Abstract]   [Full Text] [Related]  

  • 12. The quadrivalent human papillomavirus vaccine: potential factors in effectiveness.
    Zonfrillo NJ; Hackley B
    J Midwifery Womens Health; 2008; 53(3):188-194. PubMed ID: 18455092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [HPV vaccine: making decisions in public health].
    Ciofi degli Atti ML; Donati S; Salmaso S
    Epidemiol Prev; 2007; 31(4):181-2. PubMed ID: 18019199
    [No Abstract]   [Full Text] [Related]  

  • 14. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil): profile report.
    Siddiqui MA; Perry CM
    BioDrugs; 2006; 20(5):313-6. PubMed ID: 17025377
    [No Abstract]   [Full Text] [Related]  

  • 15. Public health: Prevention comes of age.
    Eisenstein M
    Nature; 2012 Aug; 488(7413):S11-3. PubMed ID: 22932434
    [No Abstract]   [Full Text] [Related]  

  • 16. Vaccination: A durable design.
    Sanderson K
    Nature; 2012 Aug; 488(7413):S7. PubMed ID: 22932439
    [No Abstract]   [Full Text] [Related]  

  • 17. The Health Technology Assessment of bivalent HPV vaccine Cervarix in Italy.
    La Torre G; de Waure C; Chiaradia G; Mannocci A; Capri S; Ricciardi W
    Vaccine; 2010 Apr; 28(19):3379-84. PubMed ID: 20197141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inferior vaccine against human papillomavirus].
    Moi H
    Tidsskr Nor Laegeforen; 2017 May; 137(10):700. PubMed ID: 28551965
    [No Abstract]   [Full Text] [Related]  

  • 19. [Progress and challenges on HPV vaccination].
    Yoshikawa H
    Uirusu; 2009 Dec; 59(2):243-8. PubMed ID: 20218332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interim statement on HPV immunization.
    Davis DB; Lalonde AB
    J Obstet Gynaecol Can; 2007 Jan; 29(1):61, 62. PubMed ID: 17346478
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.